Skip to content
2000
Volume 4, Issue 4
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

A unique pyrrolidinone-based CCR2 antagonist with sub-micromolar in vitro activities, good selectivity, and reasonable ADME properties was identified following a screening campaign and subsequent hit-to-lead medicinal chemistry efforts. We now describe further modification of this lead molecule to provide compounds with excellent DMPK profiles and significantly enhanced in vitro activities.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/157018007784619989
2007-06-01
2026-01-21
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/157018007784619989
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test